**MINUTES**

**CPIC CONFERENCE CALL**

DATE: November 4, 2021

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a doodle link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Kelly will send the poll link. |
| G6PD guideline update | Mary presented the status of the G6PD guideline update. While the 2014 G6PD guideline focused on rasburicase, the guideline update will include many more drugs. Historically, many drugs have been classified as conferring increased risk of acute hemolytic anemia (AHA) in patients with G6PD deficiency. These classifications may be conflicting depending on the source, and evidence may be sparce. The authors conducted an extensive literature review on 48 drugs that have been associated with G6PD deficiency by one or more sources (e.g., regulatory agency labeling). These drugs have been classified as high, medium, or low-to-no risk for AHA in the setting of G6PD deficiency based on the systematic literature review. High risk drugs should be avoided in G6PD deficiency, medium risk drugs should be used with caution in G6PD deficiency, and low-to-no risk drugs can be used without regard to G6PD status. Some drugs were assigned ‘no recommendation’ because of a complete lack of published evidence for the association. | The G6PD guideline authors will work towards finalizing the guideline recommendations and manuscript. |